159 related articles for article (PubMed ID: 7964953)
21. Is the prognosis of stage 4s neuroblastoma in patients 12 months of age and older really excellent?
Iehara T; Hiyama E; Tajiri T; Yoneda A; Hamazaki M; Fukuzawa M; Hosoi H; Sugimoto T; Sawada T
Eur J Cancer; 2012 Jul; 48(11):1707-12. PubMed ID: 22305511
[TBL] [Abstract][Full Text] [Related]
22. Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution.
Evans AE; Silber JH; Shpilsky A; D'Angio GJ
J Clin Oncol; 1996 Sep; 14(9):2504-10. PubMed ID: 8823329
[TBL] [Abstract][Full Text] [Related]
23. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
24. Experience with International Neuroblastoma Staging System and Pathology Classification.
Ikeda H; Iehara T; Tsuchida Y; Kaneko M; Hata J; Naito H; Iwafuchi M; Ohnuma N; Mugishima H; Toyoda Y; Hamazaki M; Mimaya J; Kondo S; Kawa K; Okada A; Hiyama E; Suita S; Takamatsu H
Br J Cancer; 2002 Apr; 86(7):1110-6. PubMed ID: 11953858
[TBL] [Abstract][Full Text] [Related]
25. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study.
Nickerson HJ; Matthay KK; Seeger RC; Brodeur GM; Shimada H; Perez C; Atkinson JB; Selch M; Gerbing RB; Stram DO; Lukens J
J Clin Oncol; 2000 Feb; 18(3):477-86. PubMed ID: 10653863
[TBL] [Abstract][Full Text] [Related]
26. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.
London WB; Castleberry RP; Matthay KK; Look AT; Seeger RC; Shimada H; Thorner P; Brodeur G; Maris JM; Reynolds CP; Cohn SL
J Clin Oncol; 2005 Sep; 23(27):6459-65. PubMed ID: 16116153
[TBL] [Abstract][Full Text] [Related]
27. Surgicopathologic staging of neuroblastoma: prognostic significance of regional lymph node metastases.
Hayes FA; Green A; Hustu HO; Kumar M
J Pediatr; 1983 Jan; 102(1):59-62. PubMed ID: 6848729
[TBL] [Abstract][Full Text] [Related]
28. Survival outcome of intermediate risk neuroblastoma at Children Cancer Hospital Egypt.
Elzomor H; Ahmed G; Elmenawi S; Elkinaai N; Refaat A; Soliman S; Abdelwahab MA; Zaghloul MS; Fawzy M
J Egypt Natl Canc Inst; 2018 Mar; 30(1):21-26. PubMed ID: 29428371
[TBL] [Abstract][Full Text] [Related]
29. Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.
Twist CJ; Schmidt ML; Naranjo A; London WB; Tenney SC; Marachelian A; Shimada H; Collins MH; Esiashvili N; Adkins ES; Mattei P; Handler M; Katzenstein H; Attiyeh E; Hogarty MD; Gastier-Foster J; Wagner E; Matthay KK; Park JR; Maris JM; Cohn SL
J Clin Oncol; 2019 Dec; 37(34):3243-3255. PubMed ID: 31386611
[TBL] [Abstract][Full Text] [Related]
30. Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification.
Bender HG; Irwin MS; Hogarty MD; Castleberry R; Maris JM; Kao PC; Zhang FF; Naranjo A; Cohn SL; London WB
J Clin Oncol; 2023 Jun; 41(17):3149-3159. PubMed ID: 37098238
[TBL] [Abstract][Full Text] [Related]
31. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study.
Perez CA; Matthay KK; Atkinson JB; Seeger RC; Shimada H; Haase GM; Stram DO; Gerbing RB; Lukens JN
J Clin Oncol; 2000 Jan; 18(1):18-26. PubMed ID: 10623689
[TBL] [Abstract][Full Text] [Related]
32. [Neuroblastoma in children under than 1 year of age].
Castel Sánchez V; Melero Moreno C; García-Miguel García-Rosados P; Navajas Gutiérrez A; Ruiz Jiménez JI; Navarro Fos S; Garín Valle JC; Galbe Sada M
An Esp Pediatr; 1997 Dec; 47(6):584-90. PubMed ID: 9575117
[TBL] [Abstract][Full Text] [Related]
33. [Neuroblastoma: biological markers, surgery, and clinical course].
Martínez Ibáñez V; Abad P; Gallego S; Sánchez de Toledo J; Marqués A; Boix Ochoa J
Cir Pediatr; 2000 Apr; 13(2):47-53. PubMed ID: 12602001
[TBL] [Abstract][Full Text] [Related]
34. [Correlation between typing of peripheral neuroblastic tumors and prognosis: a clinicopathologic study of 135 cases].
YIN MZ; ZHANG ZD; MA J; SHEN P; CHEN JF; ZHANG HZ
Zhonghua Bing Li Xue Za Zhi; 2011 Mar; 40(3):151-5. PubMed ID: 21575383
[TBL] [Abstract][Full Text] [Related]
35. Influence of image-defined risk factors on the outcome of patients with localised neuroblastoma. A report from the LNESG1 study of the European International Society of Paediatric Oncology Neuroblastoma Group.
Monclair T; Mosseri V; Cecchetto G; De Bernardi B; Michon J; Holmes K
Pediatr Blood Cancer; 2015 Sep; 62(9):1536-42. PubMed ID: 25663103
[TBL] [Abstract][Full Text] [Related]
36. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
[TBL] [Abstract][Full Text] [Related]
37. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study.
Schmidt ML; Lukens JN; Seeger RC; Brodeur GM; Shimada H; Gerbing RB; Stram DO; Perez C; Haase GM; Matthay KK
J Clin Oncol; 2000 Mar; 18(6):1260-8. PubMed ID: 10715296
[TBL] [Abstract][Full Text] [Related]
38. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.
Ravindranath Y; Chang M; Steuber CP; Becton D; Dahl G; Civin C; Camitta B; Carroll A; Raimondi SC; Weinstein HJ;
Leukemia; 2005 Dec; 19(12):2101-16. PubMed ID: 16136167
[TBL] [Abstract][Full Text] [Related]
39. Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group.
Park JR; Villablanca JG; London WB; Gerbing RB; Haas-Kogan D; Adkins ES; Attiyeh EF; Maris JM; Seeger RC; Reynolds CP; Matthay KK;
Pediatr Blood Cancer; 2009 Jan; 52(1):44-50. PubMed ID: 18937318
[TBL] [Abstract][Full Text] [Related]
40. [Value of prognostic factors in the Austrian A-NB87 Neuroblastoma Study].
Ladenstein R; Ambros PF; Urban C; Ambros IM; Fink FM; Zoubek A; Grienberger H; Schmitt K; Kerbl R; Horcher E; Amann G; Höfler G; Heinzl H; Gadner H; Mutz I
Klin Padiatr; 1996; 208(4):210-20. PubMed ID: 8926686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
